Fludarabine/cyclophosphamide

Phase 1Small molecule

PPaolo Caimi, MD

Fludarabine/cyclophosphamide is one of 48 small molecule programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Non-Hodgkin LymphomaNot yet recruiting

LymphomaPhase 1

Active, not recruiting

Non-Hodgkin LymphomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Zofran

Novartis

Preclinical

2 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 10

PEG-Intron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Non-Hodgkin Lymphoma

NCT07225439

Clinical

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

Not yet recruiting·PPaolo Caimi, MD·Phase 1·NCT07225439·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fludarabine/cyclophosphamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fludarabine/cyclophosphamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fludarabine/cyclophosphamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paolo Caimi, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPaolo Caimi, MD

Fludarabine/cyclophosphamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Non-Hodgkin Lymphoma1 trial

References

Drug Info

Quick Facts

Related News